Page 7,150«..1020..7,1497,1507,1517,152..7,1607,170..»

Online Clinical Education Platform Pedagogy Gains in Popularity

Posted: Published on February 13th, 2012

Husband and Wife Team Up to Develop Successful Formula for Delivering Valuable Courses to Health Care Professionals Tyler, TX (PRWEB) February 13, 2012 Realizing the need for an efficient and effective means to provide educational and training courses for nurses, nurse practitioners, physicians, pharmacists, nurse aids and medical assistants, Patrick and Capra Dalton decided to apply their respective skills to create Pedagogy, Inc. As a consultant for a national pharmacy company serving long term care facilities, Capra Dalton, RN and Pedagogy CEO, previously traveled throughout the state of Texas teaching infusion therapy to nurses within a traditional classroom setting. “I began to notice that nurses were having difficulty travelling to locations for these two-day courses due to conflicts with their typical work schedules, child care issues, travel expenses, and of course, ensuring proper coverage at the nursing homes where they worked,” observed Capra. Relaying her experiences to her husband, Patrick Dalton, Capra was at first skeptical about Patrick’s suggestion that the courses could be delivered online. However the more Capra thought about Patrick’s idea, the more the it took hold, “I realized that these classes could be presented in an online format and resolve so many barriers that traditional classroom … Continue reading →

Posted in Online Pharmacy | Comments Off on Online Clinical Education Platform Pedagogy Gains in Popularity

Comprehensive Care Corporation, Tampa, Florida, Offers New Pharmacy Management Initiative Designed to Reduce …

Posted: Published on February 13th, 2012

TAMPA, Fla., Feb. 13, 2012 /PRNewswire/ -- Comprehensive Care Corporation ("CompCare" or the "Company") (OTCBB: CHCR.OB - News) today announced that it has launched its innovative new pharmacy management program designed to substantially lower prescription drug costs in California. "This is an innovative initiative, which has provided us with the ability, in almost every case, to materially lower the costs of prescription drugs for our clients. An example, outside of California, is noteworthy.  One of our HMO clients is at risk for its member's prescription drugs and spends approximately $300 million annually.  After analyzing the drug spend, CompCare offered to go at full risk for the identical drugs for only $270 million.  If the client accepts this proposal, it would totally eliminate the client's drug cost risk, providing the client an immediate $30 million savings to its bottom line over its previous year drug spend," said Clark A. Marcus, Chairman and CEO. "We are able to provide savings because of our affiliation with a major retailer, affording us significantly lower prices," Mr. Marcus explained. "In California, at CompCare's sole cost and expense, we will conduct a detailed analysis of any potential client's pharmacy costs over any selected 90-day period.  Based on … Continue reading →

Posted in Pharmacy | Comments Off on Comprehensive Care Corporation, Tampa, Florida, Offers New Pharmacy Management Initiative Designed to Reduce …

ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from …

Posted: Published on February 13th, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was treated on Monday (Feb. 6) by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and retina division chief at UCLA’s Jules Stein Eye Institute. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully. “With the treatment of this third Stargardt’s patient at Jules Stein Eye Institute, we have now completed the treatment of the first cohort of patients under our clinical protocol for phase I/II of our U.S. SMD trial,” said Gary Rabin, chairman and chief executive officer of ACT. “We will continue to regularly monitor the three SMD patients in this trial, and by early spring anticipate review of their progress and safety-related data by the Data and Safety Monitoring Board (DSMB). With approval of the DSMB, we would then advance to the next cohort of patients and administer a … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from …

The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell …

Posted: Published on February 13th, 2012

JERUSALEM--(BUSINESS WIRE)-- Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, multi-center, pivotal registration, Phase III clinical trial of StemEx, a cell therapy product in development as an alternative therapeutic treatment for adolescents and adults, with blood cancers such as leukemia and lymphoma, who cannot find a family related, matched bone marrow donor. StemEx is a graft of an expanded population of stem/progenitor cells, derived from part of a single unit of umbilical cord blood and transplanted by IV administration along with the remaining, non-manipulated cells from the same unit. Dr. Yael Margolin, president and chief executive officer of Gamida Cell, said, "The JV is planning to announce the safety and efficacy results of the Phase III StemEx trial in 2012 and to launch the product into the market in 2013. It is our hope that StemEx will provide the answer for the thousands of leukemia and lymphoma patients unable to find a matched, related bone marrow donor.” Dr. Margolin continued, “StemEx may be the first allogeneic cell therapy to be brought to market. This is a source of … Continue reading →

Comments Off on The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell …

Discovery of how infection triggers blood stem cell growth

Posted: Published on February 13th, 2012

Friday, 10 February 2012, 11:06 am Press Release: University of Auckland New Zealand scientists discover how infection triggers blood stem cell growth Research at The University of Auckland has shed light on an area of medicine which has intrigued the international scientific community for decades. Scientists at the Faculty of Medical and Health Sciences have identified a molecular mechanism which links infection to an increase in rare blood stem cells in an animal. Their paper was published today in the prestigious Boston-based journal Cell Stem Cell. This high impact journal publishes novel results of unusual significance in the field of stem cell research. The findings show blood stem and progenitor cells can directly react to inflammatory stress by proliferating and differentiating into the required mature blood cells. The discovery opens up a field of study into stem cells and how the blood system is “fine-tuned” in response to stressors. This new understanding of exactly how microbes signal to the stem cells has important implications for the treatment of infections and many diseases that have an inflammatory component, including cancer. “The longer term impact could be significant in terms of how stem cell growth and development can be manipulated therapeutically. There … Continue reading →

Posted in Cell Medicine | Comments Off on Discovery of how infection triggers blood stem cell growth

American CryoStem Joins Alliance for Regenerative Medicine

Posted: Published on February 13th, 2012

RED BANK, NJ--(Marketwire -02/08/12)- American CryoStem Corporation (OTCQB: CRYO.OB - News), a commercial developer, manufacturer and marketer of clinical products and services involving adipose tissue and adipose derived adult stem cells, announced its association with the Alliance for Regenerative Medicine (ARM). ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. American CryoStem's decision to join ARM was based on the alignment of its ongoing mission to offer the highest quality products and services to help accelerate the regenerative medicine industry and ARM's support of policy efforts toward safe and reliable cellular products. Morrie Ruffin, Managing Director for the Alliance for Regenerative Medicine, commented, "We are delighted to have American CryoStem as part of the Alliance and look forward to working together to advance the field of adipose-derived stem cells for a variety of therapeutic applications." ARM's membership is diverse, representing leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research and other organizations supporting regenerative medicine. American CryoStem has created and commercialized core proprietary products and platforms for processing, storing and quality management of … Continue reading →

Posted in Cell Medicine | Comments Off on American CryoStem Joins Alliance for Regenerative Medicine

Study finds elevated levels of cell-free DNA in first trimester do not predict preeclampsia

Posted: Published on February 13th, 2012

Public release date: 11-Feb-2012 [ | E-mail | Share ] Contact: Vicki Bendure vicki@bendurepr.com 202-374-9259 Society for Maternal-Fetal Medicine DALLAS (February 11, 2012) ? In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ?, in Dallas, Texas, researchers will report findings that indicate that elevated levels of cell-free DNA in the first trimester do not predict the subsequent development of preeclampsia. "I wanted to identify if elevated levels of cell-free fetal DNA in maternal blood early in pregnancy could identify women at risk for the subsequent development of preeclampsia. I found that there is no significant difference in levels of total or free fetal DNA in the first trimester in women who subsequently develop preeclampsia," said Bob Silver, MD, with the University of Utah Health Sciences Center and Intermountain Healthcare, Obstetrics and Gynecology, in Salt Lake City, Utah. Silver conducted the study, entitled First Trimester Free Fetal DNA in The Maternal Circulation as a Predictor of Preeclampsia. ### A copy of the abstract is available at http://www.smfmnewsroom.org/annual-meeting/2011-meeting-abstracts/. For interviews please contact Vicki Bendure at Vicki@bendurepr.com, 540-687-3360 (office) or 202-374-9259 (cell), or Jacqueline Boggess at jacqueline@bendurepr.com, 540-687-5399 (office) or 202-738-3054 (cell). The … Continue reading →

Posted in Cell Medicine | Comments Off on Study finds elevated levels of cell-free DNA in first trimester do not predict preeclampsia

US begins stem cell trial for hearing loss

Posted: Published on February 13th, 2012

US researchers have begun a groundbreaking trial to test the potential of umbilical cord blood transplants, a kind of stem cell therapy, to treat and possibly reverse hearing loss in infants. The phase I trial follows promising studies on mice showing that such transplants were able to rebuild the structures of the inner ear, and some anecdotal evidence from humans, sparking hope of a cure for some forms of deafness. One of those people is two-year-old Finn McGrath, who suffered brain damage after being deprived of oxygen during a prolonged and complicated delivery, according to his mother, Laura. "His doctors told us he was at high risk for cerebral palsy, vision issues, hearing problems and mental retardation," she said in an interview with AFP. Finn's early days were an all-out struggle to survive, so for his parents, learning that he had failed his hearing tests and had damaged hair cells -- the sensory receptors in the inner ear that pick up sounds -- was almost an afterthought. He had organ failure, breathing problems, and his cerebral palsy left him unable to roll, crawl or walk, hold his head up, talk or eat. As his parents searched for ways to help … Continue reading →

Posted in Cell Therapy | Comments Off on US begins stem cell trial for hearing loss

Stem Cell Therapy for Deafness

Posted: Published on February 13th, 2012

MANILA, Philippines - US researchers have begun a groundbreaking trial to test the potential of umbilical cord blood transplants, a kind of stem cell therapy, to treat and possibly reverse hearing loss in infants. The Phase I trial follows promising studies on mice showing that such transplants were able to rebuild the structures of the inner ear, and some anecdotal evidence from humans, sparking hope of a cure for some forms of deafness. One of those people is two-year-old Finn McGrath, who suffered brain damage after being deprived of oxygen during a prolonged and complicated delivery, according to his mother, Laura. "His doctors told us he was at high risk for cerebral palsy, vision issues, hearing problems, and mental retardation," she said in an interview with AFP. Finn's early days were an all-out struggle to survive, so for his parents, learning that he had failed his hearing tests and had damaged hair cells - the sensory receptors in the inner ear that pick up sounds - was almost an afterthought. He had organ failure, breathing problems, and his cerebral palsy left him unable to roll, crawl, or walk, hold his head up, talk, or eat. As his parents searched for … Continue reading →

Posted in Cell Therapy | Comments Off on Stem Cell Therapy for Deafness

Side-effects of FDA ruling on pharma companies

Posted: Published on February 13th, 2012

The regulatory violations by pharma companies are best seen as regular business challenges than as some conspiracy from a Robin Cook novel. February 11, 2012:   What's common between Ranbaxy, Sun Pharma, Dr Reddy's, Cadila Healthcare and Aurobindo Pharma? Well, aside of the fact that they are Indian pharmaceutical companies, there's another commonality — they have all been rapped on their knuckles by the United States Food and Drug Administration (US FDA) for having transgressed regulatory norms. And behold, the list isn't exhaustive. There are many more Indian companies that have erred on FDA's wrong side, albeit for reasons varying in their severity. While some have managed to right the wrongs that the regulator had highlighted, the others are in the process of doing so. So, what do these increasing instances of regulatory non-compliance say about Indian pharmaceutical companies? Here's a look at the ramifications of the growing non-compliance issues on the Indian pharma industry. Industry's Achilles Heel With power comes responsibility. But with growth comes greater attention. This is something that Indian companies have increasingly come to realise. Having scaled up very aggressively in the last few years, be it in terms of the number of manufacturing plants they operate … Continue reading →

Posted in Drug Side Effects | Comments Off on Side-effects of FDA ruling on pharma companies

Page 7,150«..1020..7,1497,1507,1517,152..7,1607,170..»